Cellebrite DI Raises FY2023 Sales Guidance from $305.00M-315.00M to $310.00M-320.00M vs. $310.75M Estimate
Portfolio Pulse from Benzinga Newsdesk
Cellebrite DI has raised its FY2023 sales guidance from $305.00M-$315.00M to $310.00M-$320.00M, compared to the $310.75M estimate. The company's updated expectations also include an increase in growth over 2022, December 2023 ARR, 2023 Adjusted EBITDA, and 2023 Adjusted EBITDA margin.
August 08, 2023 | 11:10 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cellebrite DI's raised FY2023 sales guidance could potentially lead to a positive impact on its stock price in the short term.
The company's raised sales guidance indicates a positive outlook for its future performance, which could potentially attract investors and drive up the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100